Rucaparib May Potentially Benefit Patients with Advanced Pancreatic Cancer
May 23rd 2018Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.
Read More
Avatrombopag Gains FDA Approval for Patients with Chronic Liver Disease
May 22nd 2018The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.
Read More
FDA Warns of Decreased Survival in Some Patients Treated with Keytruda, Tecentriq Monotherapy
May 22nd 2018Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.
Read More